证券日报网讯 8月5日晚间，华大智造发布公告称，公司于2025年4月24日召开第二届董事会第十二次会 议、第二届监事会第十二次会议，审议通过了《关于使用部分暂时闲置自有资金及募集资金进行现金管 理的议案》。在满足日常经营需求的情况下，拟使用最高额不超过人民币20亿元（含本数）的闲置自有 资金及最高额不超过人民币17亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好的存款类产品或保本型产品，上述额度自公司董事会审议通过之日起12个月内有效，在前述额 度和期限范围内，资金可循环滚动使用。近日，公司开立了募集资金现金管理专用结算账户。 （文章来源：证券日报） ...

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. plans to cancel part of the restricted stock incentive plan for 2024 due to certain conditions not being met, including the departure of some incentive targets and failure to achieve performance assessment indicators [2][11][14]. Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the cancellation of the restricted stock, in accordance with relevant laws and regulations [11][17]. - The approval process included resolutions from the board of directors and supervisory board, as well as independent director opinions [7][10]. Group 2: Specifics of the Cancellation - A total of 337,150 shares of the second category of restricted stock will be canceled, which includes 188,000 shares due to 13 incentive targets leaving the company and 318,350 shares due to unmet performance criteria [11][14]. - The performance assessment for the incentive plan is based on the company's revenue growth, with a baseline of 2.709 billion yuan for 2023 [12][13]. Group 3: Information Disclosure - The company will disclose relevant documents related to the cancellation, including resolutions from the board and supervisory board meetings [15][16]. - The company is required to continue fulfilling its information disclosure obligations as per applicable laws and regulations [16][17].

Core Viewpoint - The recent funding round for Chasing Light Biotechnology aims to enhance its optoelectronic microfluidic product line, develop bio-MEMS applications, and expand its marketing network, thereby promoting the localization of high-end life science instruments [2]. Group 1: Company Overview - Chasing Light Biotechnology was founded in 2023 by professors from Beijing Institute of Technology, Southern University of Science and Technology, and Jinan University, along with several overseas PhDs [2]. - The company focuses on empowering life sciences through technology, aiding biomedicine and gene therapy, and accelerating the transformation of scientific research achievements [2]. - Chasing Light develops high-end life science instrument platforms to address critical technological challenges in the field [2][11]. Group 2: Product Offerings - The company offers products including an optoelectronic microfluidic platform, digital microfluidic platform, structured light projection devices, and microscope accessories [2]. - The OptoBot® 1000 single-cell optoelectronic microfluidic system utilizes optical tweezers and fully automated microfluidic chip principles to reduce experimental cycles from 2-3 months to 1-2 weeks while saving labor and consumable costs [3]. - The DropletBot® digital microfluidic platform is based on electrowetting principles, allowing precise control of discrete droplets for applications in biology and chemistry [6]. - The OptoNeuroBot® structured light projector employs digital micromirror device technology for precise spatial and temporal light control, compatible with mainstream microscopes [7]. Group 3: Team Expertise - The core team includes professionals with extensive experience in medical device development, project management, and financial management across various industries [11][12][13][15]. - The team combines expertise from academia and industry to continuously develop new instrument platforms in the life sciences field [11].

Group 1 - The company's revenue for Q1 2025 is 455 million yuan, representing a year-on-year decline of 14.26% [1] - The company reported a net loss of 133 million yuan, an improvement compared to a net loss of 201 million yuan in the same period last year [1]